In BCP-ALL PDXs that responded synergistically to VEN+AUR (Fig. 2B and Supplementary Figs. 4 and 5) we found no point mutations of TP53 (data not shown), which is consistent with the rare occurrence of TP53 mutations in BCP-ALL [32]. This evidence concerns the gene TP53 and acute lymphoblastic leukemia.